EGFR and central nervous system cancer: These results are particularly promising, suggesting that aMRI may play a role in the in-vivo detection of these novel GBM markers, not only aimed at an optimized diagnosis and risk stratification, but also potentially at therapy guidance, as TERT- and EGFR-targeted therapy [80,81] have been explored for gliomas.